Psilocybin in HIV Care: Demoralisation, Shame and Psychological Recovery

Andrew T. Austin · 11 October 2026

Effective HIV treatment can provide sustained viral suppression while psychological suffering remains unresolved. Bereavement, stigma, isolation and a loss of purpose may continue long after the immediate medical crisis has passed. Psilocybin-assisted therapy has been investigated for demoralisation and shame in a small group of older people living with HIV. The findings concern psychological distress; they do not establish an antiviral treatment.

On this page

• Psychological recovery after long-term survival
• The demoralisation pilot
• What changed in HIV-related shame?
• Safety includes more than the absence of a serious drug reaction
• Psychological change and HIV control are separate outcomes
• Medication and physical health require continuing care
• Group therapy, privacy and choice
• What a useful next trial would establish

Psychological recovery after long-term survival

Demoralisation describes suffering marked by helplessness, difficulty coping and a diminished sense of meaning or purpose. It may accompany depression but is not identical to it. Someone may continue to value relationships or enjoy particular activities while feeling unable to envisage a worthwhile future. Clinical assessment needs to identify the person’s specific difficulties rather than assume that all distress reflects one diagnosis.¹

For some long-term survivors, the context includes repeated bereavement, discrimination and years spent expecting a shortened life. Improved medical prognosis does not necessarily resolve those experiences. Conversely, these concerns should not be assumed to affect everyone with HIV: histories, identities, social resources and treatment experiences vary considerably.

HIV-related shame refers to a painful negative judgement of oneself in relation to HIV. It should be distinguished from external stigma and discrimination. Treatment can help a person relate differently to self-critical beliefs, but responsibility for discriminatory behaviour remains with those enacting it. A clinical formulation should not convert prejudice experienced by a patient into evidence of personal defect.

The demoralisation pilot

An open-label study enrolled 18 self-identified gay men who were older long-term AIDS survivors with moderate-to-severe demoralisation. Treatment combined eight to ten group-therapy visits with one individually supported psilocybin session. All 18 received the intervention and completed the primary endpoint and three-month safety follow-up. The mean reduction on the Demoralization Scale-II at three-month follow-up was approximately 5.8 points.¹

The finding suggests potential benefit and shows that a relatively intensive programme could be delivered to this selected population. It does not show which component produced the improvement. Participants received preparation, sustained contact with therapists and peers, the drug session and subsequent support. Without a comparison group, changes attributable to these elements, expectation and the natural course of distress cannot be separated.

The participants’ shared history was an intentional part of the group design. That may have helped establish trust, but it also narrows generalisability. The results do not automatically describe younger adults, women, gender-diverse people, people recently diagnosed with HIV or those experiencing different patterns of illness and social exclusion.¹

What changed in HIV-related shame?

A later analysis examined shame measures collected from 12 participants in the final two groups of the original programme. Median HIV-related shame scores decreased by 5.5 points from baseline to three-month follow-up. The change was statistically significant within that sample, but the design remained uncontrolled.²

These 12 participants were not a second independent clinical trial. Counting the original report and the later analysis as two separate demonstrations of treatment effectiveness would exaggerate the evidence. The later publication adds a different outcome from an overlapping sample.

The distinction between types of shame was also important. Sexual abuse-related shame did not show a significant overall pre-to-post reduction. Two participants experienced increased sexual abuse-related shame after treatment. Thus, an improvement in one area of self-evaluation did not ensure improvement in every area of trauma-related distress.²

Safety includes more than the absence of a serious drug reaction

In the original study, no serious adverse event was attributed to psilocybin. Seven participants nevertheless experienced severe, self-limited expected reactions, and two unexpected reactions occurred after administration. Acute reactions included anxiety and increases in blood pressure. “Severe” describes intensity, while “serious” is a separate classification concerned with consequences such as hospitalisation or threat to life.¹

Serious medical and psychiatric events did occur during the wider study period and were judged unrelated to psilocybin by the investigators. The report included a suicide attempt during follow-up. It would therefore be inaccurate to summarise the programme as having no serious events at all. Attribution is a clinical judgement; an uncontrolled study of this size cannot provide a reliable estimate of rare treatment-related harms.¹

Clinical support also needs to account for the content of distress. Greater willingness to discuss painful experiences may be helpful, but disclosure and improvement are different outcomes. Follow-up should assess whether the person is sleeping, functioning and feeling safer, rather than assuming that an emotionally intense account represents therapeutic progress.

Psychological change and HIV control are separate outcomes

Participants were taking antiretroviral therapy and were virologically suppressed. Medication adherence in the original pilot averaged approximately 99% at baseline, leaving little room to demonstrate further improvement. The possibility that reducing shame could help engagement with care is reasonable to investigate, but it remains a hypothesis rather than an established clinical outcome.¹²

Antiretroviral treatment has demonstrated benefits for viral suppression, immune function, survival and prevention of transmission. Those outcomes should not be attributed to a psychological intervention merely because it is delivered within HIV care.³

Medication and physical health require continuing care

HIV care commonly involves coordination between medical and mental-health treatment. Symptoms may reflect depression or anxiety, medication effects, sleep disturbance, substance use or other health problems. A medication review should consider the full regimen and potential interactions, with HIV and mental-health clinicians communicating as appropriate.⁴

The pilot cannot establish compatibility with every contemporary antiretroviral regimen or every coexisting medical condition. A favourable result in participants receiving specialist assessment does not constitute a general interaction clearance. Practical assessment must consider cardiovascular health, current psychiatric stability and the support available if symptoms worsen.

Group therapy, privacy and choice

A group can offer recognition and reduce isolation, but participation involves choices about privacy. HIV status, sexuality, bereavement and trauma may be sensitive matters. A responsible programme should explain confidentiality expectations, the limits of what staff can guarantee about other participants, and the person’s freedom not to disclose a particular experience.

Shared identity can contribute to a sense of belonging without ensuring that every participant feels safe or understood. Individual follow-up remains necessary when group dynamics increase self-criticism or distress. The later shame analysis describes this possibility and reinforces the need to evaluate each person’s course rather than rely solely on average improvement.²

What a useful next trial would establish

A controlled study should compare the intervention with credible psychological care, distinguish drug effects from group support and include a broader range of people living with HIV. Outcomes should cover meaning, depression, shame, daily function and adverse experiences. Engagement with HIV care, adherence and virological measures would need explicit assessment if medical benefits were claimed.

Longer follow-up is also needed to establish whether gains persist and what additional care is required. For current clinical practice, depression, anxiety, trauma symptoms and suicidal thinking warrant assessment and established treatment regardless of interest in psychedelics.⁴ The early findings justify further investigation of psychological recovery in HIV care, while leaving substantial questions about effectiveness, safety and applicability unresolved.

References

1. Anderson BT, Danforth A, Daroff PR, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. 2020;27:100538. doi:10.1016/j.eclinm.2020.100538.
2. Mehtani NJ, Johnson MO, Hendricks PS, et al. Psilocybin-assisted therapy and HIV-related shame. Sci Rep. 2024;14:17919. doi:10.1038/s41598-024-68908-4.
3. National Institutes of Health. Treatment Goals. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV; updated 24 September 2026.
4. HIV.gov. Mental Health. Living with HIV; accessed 11 October 2026.
5. National Institutes of Health. Interruption of Antiretroviral Therapy. Adult and adolescent antiretroviral guidelines; updated 24 September 2026.

General medical information. Decisions about treatment, medication changes and persistent symptoms require an individual assessment by an appropriately qualified clinician.